Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2018-06-12 Declaration of Voting R…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
VANHERK14June2018_NL_def.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "Transparantieverklaring" (Transparency Declaration) and explicitly states that Galapagos NV received a notification of a significant holding ('kennisgeving van belangrijke deelneming') from Van Herk Investments B.V. It details the number of voting rights (10.02%) acquired, which crossed a notification threshold (10%). This content directly corresponds to the definition of a Major Shareholding Notification, which involves reporting changes in significant share ownership levels crossing thresholds, as defined by the filing code MRQ.
2018-06-12 Dutch
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Galapagos NV, pursuant to SEC rules. It includes a press release as Exhibit 99.1 dated May 30, 2018. The document is relatively short (2801 characters) and primarily serves as a regulatory filing to report a press release. There is no substantive financial data, detailed report, or comprehensive analysis included. According to the rules, Form 6-K filings are considered Regulatory Filings (RNS) as they are miscellaneous filings that do not fit into other specific categories and often include press releases or other material information updates. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-06-05 English
GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS
Earnings Release Classification · 95% confidence The document is a press release dated May 30, 2018, announcing clinical trial results for the drug filgotinib in treating psoriatic arthritis (EQUATOR study) and providing an update on the ulcerative colitis study (SELECTION study), which resulted in a milestone payment. The text details primary endpoints (ACR20 response), safety profiles, and progression to Phase 3 for the SELECTION study. This format—a formal announcement of significant clinical data and business milestones, often issued jointly by pharmaceutical companies—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses on releasing key financial/operational results (trial success, milestone payment) rather than being a comprehensive annual report (10-K), an interim report (IR), or a transcript (CT), the most fitting category is Earnings Release (ER), as these announcements often accompany or precede formal earnings reports to disseminate critical operational news. It is not a DEF 14A (Remuneration), 10-K (Annual Report), or AR (Standalone Audit Report). It is a direct announcement of results, not just a notice that a report is attached (RPA/RNS). Q1 2018
2018-05-31 English
GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS
Regulatory Filings Classification · 95% confidence The document is a press release dated May 30, 2018, announcing clinical trial results (Phase 2 EQUATOR study in psoriatic arthritis) and the progression of another study (Phase 2b/3 SELECTION in ulcerative colitis) into Phase 3. It details efficacy endpoints (ACR20, ACR50, ACR70), safety findings, and financial milestones related to the progression. This content structure—announcing key clinical data and development milestones for an investigational drug—is characteristic of an Earnings Release (ER) or a general announcement related to R&D progress. Since it focuses on the *results* and *advancement* rather than being a formal, comprehensive financial report (like 10-K or IR), and it is a direct announcement of results, it fits best under the Earnings Release (ER) category, which often includes operational and clinical updates alongside financial highlights, or potentially a Regulatory Filing (RNS) if it were a required disclosure. Given the nature of announcing clinical trial success and progression fees, ER is the most appropriate fit among the provided options for a major operational update, although it is not strictly an 'earnings' report. However, since it is a press release announcing significant operational/clinical data, and not a formal regulatory filing like 10-K or IR, and it is not a transcript (CT) or presentation (IP), ER serves as the best fit for a major periodic announcement of company progress. The presence of forward-looking statements and contact information confirms it is a public announcement/press release.
2018-05-31 English
GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS
Regulatory Filings Classification · 95% confidence The document is a press release dated May 30, 2018, announcing clinical trial results (Phase 2 EQUATOR study in psoriatic arthritis) and the progression of another study (Phase 2b/3 SELECTION in ulcerative colitis) into Phase 3. It details efficacy endpoints (ACR20, ACR50, ACR70), safety findings, and financial milestones related to the progression. This content structure—announcing key clinical data and development milestones for an investigational drug—is characteristic of an Earnings Release (ER) or a general announcement related to R&D progress. Since it focuses on the *results* and *advancement* rather than being a formal, comprehensive financial report (like 10-K or IR), and it is a direct announcement of results, it fits best under the Earnings Release (ER) category, which often includes operational and clinical updates alongside financial highlights, or potentially a Regulatory Filing (RNS) if it were a required disclosure. Given the nature of announcing clinical trial success and progression fees, ER is the most appropriate fit among the provided options for a major operational update, although it is not strictly an 'earnings' report. However, since it is a press release announcing significant operational/clinical data, and not a formal regulatory filing like 10-K or IR, and it is not a transcript (CT) or presentation (IP), ER serves as the best fit for a major periodic announcement of company progress. The presence of forward-looking statements and contact information confirms it is a public announcement/press release.
2018-05-30 English
GILEAD EN GALAPAGOS KONDIGEN DE RESULTATEN MET FILGOTINIB AAN IN DE FASE 2 EQUATOR STUDIE IN ARTRITIS PSORIATICA EN DE VOORTGANG NAAR FASE 3 VOOR DE SELECTIE STUDIE IN COLITIS ULCEROSA
Earnings Release Classification · 95% confidence The document is a press release dated May 30, 2018, announcing clinical trial results for the drug filgotinib in treating psoriatic arthritis (EQUATOR study) and providing an update on the ulcerative colitis study (SELECTION study), which resulted in a milestone payment. The text details primary endpoints (ACR20 response), safety profiles, and progression to Phase 3 for the SELECTION study. This format—a formal announcement of significant clinical data and business milestones, often issued jointly by pharmaceutical companies—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses on releasing key financial/operational results (trial success, milestone payment) rather than being a comprehensive annual report (10-K), an interim report (IR), or a transcript (CT), the most fitting category is Earnings Release (ER), as these announcements often accompany or precede formal earnings reports to disseminate critical operational news. It is not a DEF 14A (Remuneration), 10-K (Annual Report), or AR (Standalone Audit Report). It is a direct announcement of results, not just a notice that a report is attached (RPA/RNS). Q1 2018
2018-05-30 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.